TCI GENE Inc. (TPEX:6879)

Market Cap	986.90M -32.4%
Revenue (ttm)	324.73M -6.8%
Net Income	35.80M +30.7%
EPS	1.35 +31.0%
Shares Out	26.46M
PE Ratio	27.63
Forward PE	n/a
Dividend	2.00 (5.22%)
Ex-Dividend Date	Sep 5, 2025

Volume	4,005
Average Volume	6,995
Open	36.50
Previous Close	38.30
Day's Range	36.50 - 37.30
52-Week Range	32.45 - 59.00
Beta	0.14
RSI	51.65
Earnings Date	Mar 5, 2026

About TCI GENE

TCI GENE Inc., together with its subsidiaries, provides genetic testing and assessment services in Taiwan and Mainland China. It operates through Inspection and Consumable Products segments. The company offers memory, anti-aging, health management, child growth and development, nutritional metabolism and absorption, OB weight management, and SC skin management genetic testing; gut microbiota testing; and LDT cardiovascular drug gene testing services. It also provides precision prediction and personalized health management plans; and adipose-der...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6879

Financial Performance

In 2024, TCI GENE's revenue was 347.54 million, an increase of 4.10% compared to the previous year's 333.86 million. Earnings were 56.31 million, an increase of 382.40%.